Kinetic interpretation of the importance of OATP1B3 and MRP2 in docetaxel-induced hematopoietic toxicity

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 7, 2014, Pages

  Yamada, A ^a   Maeda, K ^a   Kiyotani, K ^b,c   Mushiroda, T ^b   Nakamura, Y ^a,c   Sugiyama, Y ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

^c UNIVERSITY OF CHICAGO   (United States)

^d RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DOCETAXEL; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN SERUM ALBUMIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 1; SODIUM BILE ACID COTRANSPORTER; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TAUROCHOLIC ACID; TETRYLAMMONIUM; XANTHINE;

ALLELE; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL MATURATION; CELL PROLIFERATION; COLONY FORMATION; COMPUTER MODEL; CONTROLLED STUDY; GENE EXPRESSION SYSTEM; HEK293 CELL LINE; HOMOZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; KINETICS; LIVER CLEARANCE; MALE; MTT ASSAY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT;

EID: 84905407295     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.23     Document Type: Article

References (29)

1. Rowinsky, E.K. & Donehower, R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52, 35-84 (1991).
2. Clarke, S.J. & Rivory, L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36, 99-114 (1999).
3. Sparreboom, A. et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab. Dispos. 24, 655-658 (1996).
4. Extra, J.M., Rousseau, F., Bruno, R., Clavel, M., Le Bail, N. & Marty, M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 53, 1037-1042 (1993).
5. Baker, S.D. et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin. Pharmacol. Ther. 77, 43-53 (2005).
6. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y. & Nakamura, Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 99, 967-972 (2008).
7. Smith, N.F., Acharya, M.R., Desai, N., Figg, W.D. & Sparreboom, A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4, 815-818 (2005).
8. Baker, S.D. et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85, 155-163 (2009).
9. Huisman, M.T., Chhatta, A.A., van Tellingen, O., Beijnen, J.H. & Schinkel, A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116, 824-829 (2005).
10. Zimmermann, C., van de Wetering, K., van de Steeg, E., Wagenaar, E., Vens, C. & Schinkel, A.H. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab. Dispos. 36, 631-640 (2008).
11. Ishiguro, N. et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos. 34, 1109-1115 (2006).
12. Shimizu, M. et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33, 1477-1481 (2005).
13. Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T. & Sugiyama, Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 36, 663-669 (2008).
14. Suzuki, H. & Sugiyama, Y. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin. Liver Dis. 18, 359-376 (1998).
15. König, J., Nies, A.T., Cui, Y., Leier, I. & Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394 (1999).
16. Keppler, D., König, J. & Büchler, M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv. Enzyme Regul. 37, 321-333 (1997).
17. Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
18. Bruno, R., Vivier, N., Vergniol, J.C., De Phillips, S.L., Montay, G. & Sheiner, L.B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm. 24, 153-172 (1996).
19. Yamada, A. et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet. Genomics 21, 523-530 (2011).
20. Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034 (2001).
21. Shimizu, K. et al. Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol 39, 847-53 (2012).
22. Kato, M., Tachibana, T., Ito, K. & Sugiyama, Y. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab. Pharmacokinet. 18, 121-127 (2003).
23. Kato, K. et al. Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. Pharmacogenet. Genomics 22, 344-354 (2012).
24. Payen, L., Sparfel, L., Courtois, A., Vernhet, L., Guillouzo, A. & Fardel, O. The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol. Toxicol. 18, 221-233 (2002).
25. Maeda, K., Kambara, M., Tian, Y., Hofmann, A.F. & Sugiyama, Y. Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol. Pharm. 3, 70-77 (2006).
26. Tahara, H. et al. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm. Res. 22, 647-660 (2005).
27. Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146 (2004).
28. Yamaoka, K., Tanigawara, Y., Nakagawa, T. & Uno, T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobio-dyn. 4, 879-885 (1981).
29. Matsumura-Takeda, K., Kotosai, K., Ozaki, A., Hara, H. & Yamashita, S. Rat granulocyte colony-forming unit (CFU-G) assay for the assessment of drug-induced hematotoxicity. Toxicol. In Vitro 16, 281-288 (2002).